IMO , would it not be more prudent to approach the cardio-protection program on a higher priority to Zantrene as a FTO inhibitor ?
As you have mentioned before , getting Zantrene + doxorubicin into the hands of the oncologists would be an easier sell than as an FTO inhibitor.
We could possibly license out Zantrene to be used for the prevention of cardiotoxicity in patients receiving anthracyclines and at the same time develop the FTO program at a slower pace to ensure that we get as much data as we possibly can ?
Ann: Race Oncology Share Purchase Plan Opens, page-414
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
-0.020(1.19%) |
Mkt cap ! $282.8M | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.67 | $1.61 | $153.5K | 94.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $1.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 4080 | 1 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |